These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1117 related items for PubMed ID: 25130281

  • 1. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K.
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C.
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [Abstract] [Full Text] [Related]

  • 5. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR, Amarenco G, López Aramburu MA, Everaert K, Liehne J, Lucas M, Vik V, Ridder A, Snijder R, Yamaguchi O, BLOSSOM Investigator Group.
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A, Cardozo L, Nitti VW, Castro-Diaz D, Auerbach S, Blauwet MB, Siddiqui E.
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [Abstract] [Full Text] [Related]

  • 8. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N.
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [Abstract] [Full Text] [Related]

  • 9. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E.
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
    Yamaguchi O, Marui E, Igawa Y, Takeda M, Nishizawa O, Ikeda Y, Ohkawa S.
    Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
    [Abstract] [Full Text] [Related]

  • 11. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
    Chapple CR, Kaplan SA, Mitcheson D, Blauwet MB, Huang M, Siddiqui E, Khullar V.
    Int J Urol; 2014 Oct; 21(10):960-7. PubMed ID: 25092441
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [Abstract] [Full Text] [Related]

  • 13. Patient-reported outcomes with the β3 -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder.
    Khullar V, Amarenco G, Angulo JC, Blauwet MB, Nazir J, Odeyemi IA, Hakimi Z.
    Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
    [Abstract] [Full Text] [Related]

  • 14. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Soliman MG, El-Abd S, El-Gamal OM, Raheem AA, Abou-Ramadan AR, El-Abd AS.
    Urol Int; 2021 Nov; 105(11-12):1011-1017. PubMed ID: 34010843
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
    Ohlstein EH, von Keitz A, Michel MC.
    Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
    Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR.
    Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
    [Abstract] [Full Text] [Related]

  • 17. Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Ikeda Y, Ohkawa S.
    BJU Int; 2014 Jun; 113(6):951-60. PubMed ID: 24471907
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C.
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Robinson D.
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [Abstract] [Full Text] [Related]

  • 20. A phase II dose-ranging study of mirabegron in patients with overactive bladder.
    Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, Drogendijk T, Ridder A, Van Der Putten-Slob I, Yamaguchi O, Dragon Investigator Group.
    Int Urogynecol J; 2013 Sep; 24(9):1447-58. PubMed ID: 23471546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.